Low-dose naltrexone: harnessing the body's own chemistry to treat human ovarian cancer

Exp Biol Med (Maywood). 2011 Jul;236(7):viii. doi: 10.1258/ebm.2011.011f07.
No abstract available

Publication types

  • Comment

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Cisplatin / administration & dosage*
  • Disease Models, Animal
  • Drug Therapy, Combination / methods
  • Female
  • Humans
  • Mice
  • Naltrexone / administration & dosage*
  • Ovarian Neoplasms / drug therapy*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Naltrexone
  • Cisplatin